Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023

Table 2 Model parameter of LCTM analysis

Trajectories	BIC	Log-likelihood	AIC	Percentage of PLADs in groups
1
2	770.28	783.88	775.88	53.3; 46.7
3	830.13	850.53	838.53	49.0; 27.3; 23.7
4	No convergence

LCTM latent class trajectory models, BIC Bayesian information criterion, AIC akaike information criterion

ISSN: 2397-0642